Two non-executive directors at Hikma Pharmaceuticals have upped their stakes in the Arab world-focused pharmaceutical company.
Ronald Goode took 8,000 shares at 633p a time, lifting his stake to 22,700 shares, while Robert Pickering snapped up 7,500 shares at 617p a pop, having previously had none.
In August, Hikma said that disruption in Libya and Yemen contributed to a fall in profits at pharmaceuticals group Hikma in the half year to 30 June.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Gross profit fell to $172.6m from $178.5m over the same period the previous year, on revenues that climbed to $394.8m from $377.7m.
Gross profits in the company's branded products division fell by $3m to $99.2m due to "lost sales in Libya and Yemen and action we took to increase salaries and employee benefits across the MENA (Middle East and North Africa) region to minimise the impact of market disruptions."
Goode has 30 years' experience in the pharmaceutical industry, having previously worked at the US firms Pfizer and Searle. Pickering is a lawyer who spent 23 years at the stock broker Cazenove.
Top Director Buys
Hikma Pharmaceuticals (HIK)
Director name: Dr Ronald L Goode
Amount purchased: 8,000 @ 633.00p
Value: £50,640
Hikma Pharmaceuticals (HIK)
Director name: Mr Robert Pickering
Amount purchased: 7,500 @ 617.00p
Value: £46,275
IFG Group (IFP)
Director name: Mr Aidan Comerford
Amount purchased: 20,000 @ 100.40p
Value: £20,080
Top Director Sells
Gulfsands Petroleum (GPX)
Director name: Mr Kenneth Judge
Amount sold: 400,000 @ 191.25p
Value: £765,000
